Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1212-1217

  Arkema, Elizabeth V ^a   Jonsson, Jerker ^a,b   Baecklund, Eva ^c   Bruchfeld, Judith ^a   Feltelius, Nils ^a,d   Askling, Johan ^a   Kvien, Tore K ^e   Cöster, Lars ^e   Forsblad, Helena ^e   Geborek, Peirre ^e   Jacobsson, Lennart ^e   Klarskog, Lars ^e   Kristensen, Lars Erik ^e   Lindblad, Staffan ^e   Rantapää Dahlqvist, Solbritt ^e   Van Vollenhoven, Ronald ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SWEDEN; TUBERCULOSIS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SWEDEN; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934966001     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204960     Document Type: Article

References (30)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932-9.
2. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; (2):CD008794.
3. Keane J, Gershon S, Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
4. Wallis RS, Broder MS, Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5.
5. Mohan AK, Cote TR, Block J.A., et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39:295-9.
6. Tubach F, Salmon D, Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy the three-year prospective French research Axed on tolerance of biotherapies registry. Arthritis Rheum 2009; 60:1884-94.
7. Dixon WG, Hyrich KL, Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522-8.
8. Dixon WG, Watson K, Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy-Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368-76.
9. Gomez-Reino JJ, Carmona L, Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48:2122-7.
10. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52:1986-92.
11. Wolfe F, Michaud K, Anderson J., et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372-9.
12. Seong SS, Choi CB, Woo J.H., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34:706-11.
13. Winthrop KL, Baxter R, Liu L., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37-42.
14. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625-39.
15. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: ECDC, 2011.
16. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36:1185-206.
17. Gomez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57:756-61.
18. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69 (SUPPL. 1):i2-29.
19. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 (SUPPL. 5):v38-47.
20. Carmona L, Hernandez-Garcia C, Vadillo C., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30:1436-9.
21. Brode SK, Jamieson FB, Ng R, et al. Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. Chest 2014. doi:10.1378/chest. 13-2058 [epub ahead of print 2 Jan 2014].
22. Quality and content in the patient register. 2009. http://www.socialstyrelsen.se/publikationer2009/2009-125-15
23. Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. Bmj 2013; 346:f1939.
24. Holmqvist ME, Neovius M, Eriksson J., et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012; 308:1350-6.
25. Neovius M, Simard J, Sundstrom A., et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 2011; 70:516-19.
26. The future development of the Swedish register system. 2001. http://www.scb.se/Grupp/Hitta-statistik/Forsta-Statistik/Metod/-Dokument/RD2001-1-eng.pdf
27. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56:2896-904.
28. Winthrop KL, Weinblatt ME, Daley CL. You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71:1757-60.
29. Kleinert S, Tony HP, Krueger K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-gamma release assays under real-life conditions. Ann Rheum Dis 2012; 71:1791-5.
30. World Health Organization, Tuberculosis country profiles. 2012. [cited 2013 September 5]; http://www.who.int/tb/country/data/profiles/en/index.html